静脉注射免疫球蛋白在肝素诱导的血小板减少症中的应用及早期用药与标准治疗的疗效比较
该回顾性研究描述了10年间HIT患者IVIG的真实使用模式,并通过倾向性评分匹配比较了早期IVIG(诊断3天内)与标准治疗的疗效。
要点
- IVIG用于重症HIT患者,其血小板中位最低值为26×10^9/L,75.8%诊断时存在血栓。
- 早期IVIG(诊断3天内)较标准治疗显著加速血小板恢复,中位时间3天 vs 5天。
核心结论
- 在本机构中,IVIG仅用于血栓负荷高的重症HIT患者。
- 与标准治疗相比,早期IVIG给药可加速血小板恢复,且未观察到血栓、出血或死亡率的显著差异。
研究设计与样本
- 回顾性病历审查,覆盖Allegheny健康网络内多家医院(2015-2025年)。
- 描述所有接受IVIG的HIT患者(n=29)的特征和结局。
- 采用1:2倾向性评分匹配比较早期IVIG组(n=24,诊断3天内)与对照组(n=129)。
- 主要结局为血小板恢复时间,采用Kaplan-Meier法和Cox比例风险回归分析。
主要发现
- IVIG队列血小板中位最低值为26×10^9/L(IQR 16-35),75.8%诊断时存在血栓。
- 93.1%的患者实现血小板恢复,首次IVIG给药后中位恢复时间6天(IQR 3-9),安全性良好。
- 血栓、出血或死亡率无显著差异。
临床怎么用
- 对于血栓负荷高的重症HIT患者,可考虑使用IVIG作为辅助治疗。
- 早期(诊断3天内)给予IVIG可能加速血小板恢复。
- 需结合血小板最低值评估恢复速度,较高最低值者恢复可能更快。
局限性
- 回顾性单中心研究,样本量有限(IVIG组n=29)。
- 结果需前瞻性多中心研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an immune-mediated prothrombotic complication of heparin exposure. Intravenous immunoglobulin (IVIG) has been proposed as adjunctive therapy for refractory or autoimmune HIT. Real-world utilization patterns and the impact of early administration on clinical outcomes remain unclear. OBJECTIVES: To describe real-world utilization of IVIG in HIT over a 10-year period, and to compare platelet recovery and clinical outcomes between patients receiving early early IVIG (within 3 days of diagnosis) and those receiving standard of care alone. METHODS: We conducted a retrospective chart review across hospitals within the Allegheny Health Network (2015-2025). We described the clinical characteristics and outcomes of all HIT patients who received IVIG (n = 29). We also compared early IVIG recipients (n = 24) with controls (n = 129) using 1:2 propensity score matching. The primary outcome was time to platelet recovery, analyzed using Kaplan-Meier estimation and Cox proportional hazards regression. RESULTS: IVIG was used in a cohort of patients with a median platelet count nadir of 26 × 109/L (IQR, 16-35), and thrombosis was present at diagnosis in 75.8%. Platelet recovery was achieved in 93.1% of patients, with a median time of 6 days (IQR, 3-9) after the first IVIG dose and a favorable safety profile. Early IVIG (within 3 days of HIT diagnosis) was associated with significantly faster platelet recovery in the matched cohort (median, 3 vs 5 days; hazard ratio, 2.15; 95% CI, 1.09-4.26; P = .028). A higher platelet nadir predicted faster recovery (hazard ratio, 2.247 per 10 × 109/L; P < .001). No significant differences in thrombosis, bleeding, or mortality were observed. CONCLUSION: At our institution, IVIG use for HIT was limited to severely ill patients with a high thrombotic burden. Early IVIG administration accelerated platelet recovery compared with standard-of-care alone. Prospective multicenter studies are needed to confirm these findings.
引用
- Singh J, Gorecki G, Gill P, et al. Intravenous immunoglobulin use in heparin-induced thrombocytopenia and efficacy of early intravenous immunoglobulin compared with standard-of-care treatment. J Thromb Haemost. 2026. PMID: 42785442. doi:10.1016/j.jtha.2026.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。